This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
These cytosolic formyltransferase produce fMet-tRNAi, which can be used by cytosolic ribosomes to produce proteins with a N-terminal fMet. These proteins are targeted for degradation by specific processes in the cell.
=== MMPs regulation === Under physiological conditions, MMPs are regulated at five levels: transcription; activation of zymogen precursors; interaction with ECM components; inhibition by TIMPs; and regulated absorption/elimination of active proteases from the extracellular environment. The majority of the literature is based on an investigation of transcriptional level (level 1) modifications, which lacks information on the physiologically relevant actions and control of secreted and post-translationally activated proteases. Future study could focus on the post-transcriptional regulation of MMP activity, especially in vivo.
They called an ambulance which took him to Cedars-Sinai Medical Center, where Barker received stitches for an injured forehead and was released; he also hurt his left knee. Barker slipped and hit his head at home on June 19, 2017. His maid drove him to the emergency room, where Barker was checked and released. His representative said it was not as serious as his earlier fall. In October and November 2018, Barker was rushed to the hospital for severe back pain. Barker suffered another fall in January 2019, but he was not hospitalized. Barker's last public interview was with People in August 2021, in which he discussed The Price Is Right's upcoming 50th season on air. As of 2022, Burnet stated that, other than some non-prescription supplements such as collagen and a meal replacement drink to replenish nutrients not found naturally in Barker's vegetarian diet, he took only one prescription medication for hypothyroidism. On August 26, 2023, Barker died at his home in Los Angeles at the age of 99 of natural causes related to following several years fighting with Alzheimer's disease, a condition that Burnet and Barker's publicity team had kept hidden from the public. Hypertension, hyperlipidemia and hypothyroidism were listed as secondary causes of death. Barker was interred alongside his wife at Forest Lawn Memorial Park – Hollywood Hills.
Further separation was carried out in the presence of a citric acid/ammonium buffer solution in a weakly acidic medium (pH ≈ 3.5), using ion exchange at elevated temperature. The chromatographic separation behavior was unknown for element 97 at the time but was anticipated by analogy with terbium. The first results were disappointing because no alpha-particle emission signature could be detected from the elution product. With further analysis, searching for characteristic X-rays and conversion electron signals, a berkelium isotope was eventually detected. Its mass number was uncertain between 243 and 244 in the initial report, but was later established as 243.
== Drug development cost == The costs spent on tecemotide development – beginning in the late 1990s – have not been published in detail by the companies Biomira/Oncothyreon, Merck KGaA, and Ono Pharmaceutical. Additionally, the estimation of the full cost of bringing a new drug to market – from discovery through clinical trials to approval – is complex and controversial. However, a cautious estimate of the tecmotide development cost spent until 2014 ranges from €300 to €500 million (US$390 to US$650 million; for more information see Drug development).
Sources: en.wikipedia.org
Shōyu is officially divided into five main types by the JAS (Japanese Agricultural Standard) depending on differences in their ingredients and method of production. These types are koikuchi, usukuchi, tamari, saishikomi, and shiro. Most, but not all, Japanese soy sauces include wheat as a primary ingredient, which tends to give them a slightly sweeter taste than their Chinese counterparts. They also tend towards an alcoholic sherry-like flavor, sometimes enhanced by the addition of small amounts of alcohol as a natural preservative. The widely varying flavors of these soy sauces are not always interchangeable, so some recipes only call for one type or the other, much as a white wine cannot replace a red's flavor or beef stock does not make the same results as chicken stock. Some soy sauces made in the Japanese way or styled after them contain about 50% wheat.
Claude Monet (1840–1926), a resident of Le Havre from the age of five, in 1872 painted Impression soleil levant (Impression, Sunrise), a painting that gave its name to the impressionist movement. In 1867–1868, he painted many seascapes in the Le Havre region (Terrasse à Sainte-Adresse (Garden at Sainte-Adresse), 1867 Bateaux quittant le port (Boats Leaving the Port), 1874). The Musée Malraux houses some of his paintings : Waterlilies, London Parliament et Winter Sun at Lavacourt. Two other Impressionists, Camille Pissarro (1830–1903) and Maxime Maufra (1861–1918) also represented the port of Le Havre which also inspired Paul Signac (1863–1935), Albert Marquet (1875–1947), and Maurice de Vlaminck (1876–1958). Then came the school of Fauvism in which many artists did their training at Le Havre: Othon Friesz (1879–1949), Henri de Saint-Delis (1876–1958), Raoul Dufy (1877–1953), Georges Braque (1882–1963), Raymond Lecourt (1882–1946), Albert Copieux (1885–1956), who followed the course of the School of Fine Arts of Le Havre in the time of Charles Lhuillier. They left a number of paintings on the theme of the city and the port. In 1899, Henri de Toulouse-Lautrec (1864–1901) painted La serveuse anglaise du Star (The English waitress of Star) (Museum Toulouse-Lautrec, Albi) of a girl he met in a bar in the city. Other painters who painted Le Havre and/or its surroundings such as Sainte-Adresse can be cited in particular: Frédéric Bazille, John Gendall, Thomas Couture, Ambroise Louis Garneray, Pablo Picasso (Souvenir du Havre).
=== Triphasic bonds === Other type of "dynamic bonds" have been defined in addition to the original types of catch bonds, slip bonds and ideal bonds classified by Dembo. Unlike slip bonds, which have been observed in the entire force range tested, catch bonds only exist within certain force range as any molecular bond would eventually be overpowered by high enough force. Therefore, catch bonds are always followed by slip bonds, hence termed "catch-slip bonds". More variations have also been observed, e.g., triphasic slip-catch-slip bonds.
==== Proton abstraction ==== Proton abstraction is different from the three ionization methods mentioned above because negative ions (NI) are formed during the process rather than positive ions. (M-H)− ions are often produced in polar organics in the NI mode. The first three ionization mechanisms discussed above all have their analogues in NI-FD-MS. In field ionization, molecular anions (M− ̇ ) can be generated. Anion attachment can also lead to the formation of negative ions for some molecules, for example, (M + Cl)−. Thermal desorption usually produces anion (A−) and cluster ion (e.g. CA2−) for salts.
Trump signs a bill to fund the Department of Homeland Security, the Secret Service, the Coast Guard, FEMA, TSA, and the Cybersecurity and Infrastructure Security Agency, ending a 76-day partial government shutdown. In ice hockey, the Minnesota Wild defeat the Dallas Stars in six games in the 2026 Stanley Cup playoffs following a 5–2 victory to win a playoff series for the first time since 2015, ending an 11-year drought.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.